Incidence of Hepatotoxicity and Factors Associated During Highly Active Antiretroviral Therapy in People Living with HIV in Ethiopia: A Prospective Cohort Study

References

• UNAIDS. Global HIV & AIDS statistics — 2018 fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed March 17, 2021.
   Google Scholar
• CDC. National Center for HIV/AIDS, Viral hepatitis, STD, and TB prevention. Division of AIDS prevention. Mortality Slide Series. https://www.cdc.gov/hiv/pdf/statistics_surveillance_hiv_mortality.pdf. Accessed June 27, 2017.
   Google Scholar
• Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825–829. doi:10.1086/428093
   PubMed Web of Science ®Google Scholar
• Zhang S, Rust G, Cardarelli K, Felizzola J, Fransua M, Stringer HG Jr. Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection. AIDS Care. 2015;27(7):829–835. doi:10.1080/09540121.2015.1021745
   PubMed Web of Science ®Google Scholar
• Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24(6):915–919. doi:10.1097/QAD.0b013e3283360976
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on the Use Of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization; 2016.
   Google Scholar
• Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90–97. doi:10.1086/381444
   PubMed Web of Science ®Google Scholar
• Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198–1209. doi:10.1016/S0140-6736(10)62001-6
   PubMed Web of Science ®Google Scholar
• Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5(1):36–43.
   Google Scholar
• den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14(18):2895–2902. doi:10.1097/00002030-200012220-00011
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80. doi:10.1001/jama.283.1.74
   PubMed Web of Science ®Google Scholar
• Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186(1):23–31. doi:10.1086/341084
   PubMed Web of Science ®Google Scholar
• Hamza M, Adamu S, Maifada Y, et al. Prevalence and risk factors for hepatotoxicity among patients with HIV/AIDS on highly active antiretroviral therapy in North-Western Nigeria. Sub-Saharan Afr J Med. 2014;1(4):175–184. doi:10.4103/2384-5147.144727
   Google Scholar
• Kassa D, de Jager W, Gebremichael G, et al. The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to Mycobacterium tuberculosis (Mtb) antigens in active TB patients and latently Mtb infected individuals. Tuberculosis. 2016;96:131–140. doi:10.1016/j.tube.2015.05.015
   Web of Science ®Google Scholar
• WHO. Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme Manual. 4th ed. 2008.
   Google Scholar
• Tseng Y-T, Yang C-J, Chang S-Y, et al. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan. Int J Infect Dis. 2019;29:12–17. doi:10.1016/j.ijid.2014.08.012
   Web of Science ®Google Scholar
• Lucien K, Clement A, Fon N, Weledji P, Ndikvu C. The effects of antiretroviral treatment on liver function enzymes among HIV-Infected out-patients attending the central hospital of Yaounde, Cameroon. Afr J Clin Exp Microbiol. 2010;11(3):1595–1689.
   Google Scholar
• Shiferaw MB, Tulu KT, Zegeye AM, Wubante AA. Liver enzymes abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART naive HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: a Comparative Cross-Sectional Study. AIDS Res Treat. 2016;2016:7. doi:10.1155/2016/1985452
   Google Scholar
• Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21(10):1301–1308. doi:10.1097/QAD.0b013e32814e6b08
   PubMed Web of Science ®Google Scholar
• Kalyesubula R, Kagimu M, Opio KC, et al. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci. 2011;11(1):16–23.
   PubMed Web of Science ®Google Scholar
• Pol S, Lebra P, Vallet PA. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Inf Dis. 2004;38(Supplement_2):S65–S72. doi:10.1086/381499
   Web of Science ®Google Scholar
• Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 1997;158(3):1473–1481.
   Web of Science ®Google Scholar
• Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82. doi:10.1111/j.1572-0241.2005.00341.x
   PubMed Web of Science ®Google Scholar
• Saigal S, Nandeesh HP, Agarwal SR, Misra A, Jain SK, Sarin SK. High prevalence and profile of tuberculosis in chronic liver disease patients. Gastroenterology. 1998;114:A38. doi:10.1016/S0016-5085(98)80156-X
   Web of Science ®Google Scholar
• Sonika U, Kar P. Tuberculosis and liver disease: management issues. Trop Gastroenterol. 2012;33(2):102–106. doi:10.7869/tg.2012.25
   Google Scholar
• Gebremicael G, Kassa D, Quinten E, et al. Host gene expression kinetics during treatment of tuberculosis in HIV-coinfected individuals is independent of HAART therapy. J Infect Dis. 2018;218(11):1833–1846. doi:10.1093/infdis/jiy404
   Web of Science ®Google Scholar
• Elston JW, Thaker HK. Co-infection with human immunodeficiency virus and tuberculosis. Indian J Dermatol Venereol Leprol. 2008;74(3):194–199. doi:10.4103/0378-6323.41362
   Web of Science ®Google Scholar
• Wood S, Byrne M, Deiss R, et al. the incidence and risk factors associated with chronic liver enzyme elevation (cLEE) in HIV-monoinfected persons. Open Forum Infect Dis. 2017;4(suppl_1):S220–S221. doi:10.1093/ofid/ofx163.453
   Google Scholar
• Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis. 2005;5(1):58. doi:10.1186/1471-2334-5-58
   Web of Science ®Google Scholar
• de Castro N, Braun J, Charreau I, et al. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther. 2016;13(1):17. doi:10.1186/s12981-016-0101-3
   Web of Science ®Google Scholar